NurExone Biologic Inc. (TSXV:NRX)

NurExone Biologic Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	1.51	2.14	0.7	0.54	2.46	2.21
Cash & Short-Term Investments	1.51	2.14	0.7	0.54	2.46	2.21
Cash Growth	156.80%	205.43%	29.39%	-78.03%	11.25%	-
Other Receivables	0.15	0.09	0.13	0.1	0.05	0.52
Receivables	0.15	0.09	0.13	0.1	0.05	0.52
Inventory	-	-	0.6	-	-	-
Prepaid Expenses	-	0.1	0.17	0.11	0.12	0.09
Restricted Cash	-	0.24	-	1.2	-	-
Other Current Assets	0.04	0.04	0.04	0.03	0.05	0.02
Total Current Assets	1.71	2.6	1.63	1.98	2.69	2.84
Property, Plant & Equipment	0.82	0.86	0.81	0.19	0.1	-
Other Long-Term Assets	0.62	0.62	-	-	-	-
Total Assets	3.15	4.08	2.44	2.17	2.79	2.84

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accrued Expenses	0.45	0.69	0.34	0.55	0.46	0.18
Short-Term Debt	-	-	-	-	-	1.04
Current Portion of Leases	-	0.04	0	0.02	0.02	-
Other Current Liabilities	0.31	0.26	0.06	1.34	0.12	0.41
Total Current Liabilities	0.76	0.99	0.4	1.91	0.6	1.63
Long-Term Leases	0.07	0.07	0.03	0	0.02	-
Long-Term Unearned Revenue	0.25	0.21	0.17	-	-	-
Other Long-Term Liabilities	0.06	0.06	0.08	0.07	0.08	0.03
Total Liabilities	1.15	1.33	0.68	1.98	0.7	1.66

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Additional Paid-In Capital	26.78	26.09	19.47	12.16	11.25	3.26
Retained Earnings	-27.25	-25.48	-19.1	-14.06	-10.42	-2.25
Comprehensive Income & Other	2.47	2.15	1.4	2.08	1.26	0.17
Shareholders' Equity	2	2.76	1.76	0.19	2.1	1.18
Total Liabilities & Equity	3.15	4.08	2.44	2.17	2.79	2.84

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	0.07	0.11	0.03	0.02	0.04	1.04
Net Cash (Debt)	1.44	2.03	0.67	0.52	2.42	1.17
Net Cash Growth	158.89%	204.35%	28.02%	-78.46%	106.58%	-
Net Cash Per Share	0.02	0.03	0.01	0.01	0.06	0.07
Filing Date Shares Outstanding	92.05	92.05	78.01	65.81	42.86	34.47
Total Common Shares Outstanding	92.05	90.68	71.07	48.25	42.86	34.47
Working Capital	0.94	1.61	1.24	0.07	2.09	1.21
Book Value Per Share	0.02	0.03	0.02	0.00	0.05	0.03
Tangible Book Value	2	2.76	1.76	0.19	2.1	1.18
Tangible Book Value Per Share	0.02	0.03	0.02	0.00	0.05	0.03
Machinery	-	0.61	0.48	0.17	0.05	-
Leasehold Improvements	-	0.4	0.35	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 31, 2026

Data Sources Report a data error